Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Stanford University

Summary

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Adult kidney transplant patients. * No known contraindications to Dipyridamole Exclusion Criteria: * Contraindications to Dipyridamole. * Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation). * Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

Interventions

Drug
Dipyridamole 75 MG
Dipyridamole administered three times daily when serum phosphorus levels fall below 4 mg/dL. The drug is used off-label for this study to manage hypophosphatemia in kidney transplant recipients.

Location

Stanford University
Stanford, California
pariw@stanford.edu 650-724-8441